Jove
Visualize
Contact Us

Related Experiment Videos

What's wrong with our cancer models?

Alexander Kamb1

  • 1Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA. Alexander.Kamb@novartis.com

Nature Reviews. Drug Discovery
|February 3, 2005
PubMed
Summary

Developing new cancer drugs faces high failure rates due to flawed preclinical models. Careful selection and interpretation of these models are crucial for improving oncology drug development success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detailed analysis of the effects of a NOT gate on activation and growth of T cells.

Cytotherapy·2025
Same author

Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy.

Frontiers in immunology·2025
Same author

Editorial: The next stage of immune cell design: selective targeting of multi-antigen profiles.

Frontiers in immunology·2025
Same author

NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.

iScience·2024
Same author

Geometric parameters that affect the behavior of logic-gated CAR T cells.

Frontiers in immunology·2024
Same author

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity.

Cancer research communications·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Drug Discovery
  • Preclinical Research

Background:

  • Oncology drug development faces significant challenges, including a critical need for novel therapeutics.
  • High toxicity of cytotoxic cancer drugs and substantial Phase III trial failure rates are common.
  • Existing preclinical cancer models may be inadequate or misused, contributing to poor drug performance.

Purpose of the Study:

  • To evaluate the effectiveness of preclinical cancer models in drug development.
  • To identify factors influencing the success or failure of investigational cancer drugs.
  • To provide guidance on the appropriate selection and interpretation of cancer models.

Main Methods:

  • Review of existing studies on preclinical cancer models.
  • Analysis of factors contributing to the success and failure of cancer drug trials.
  • Comparative assessment of different types of preclinical models.

Main Results:

  • Preclinical cancer models can be highly effective when carefully chosen and interpreted.
  • Improper use or selection of models significantly impacts investigational drug outcomes.
  • Evidence suggests a strong correlation between model validity and clinical trial success.

Conclusions:

  • Optimizing the use of preclinical cancer models is essential for advancing oncology therapeutics.
  • Improved model selection and interpretation can enhance the efficiency and success rate of cancer drug development.
  • Further research into refining preclinical models is warranted to address unmet needs in cancer treatment.

Related Experiment Videos